1 Oct 2018 14:57
BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION
VERNALIS PLC (the "Company")
1 October 2018
Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Vernalis plc | |||||||||||||||||||
Name of scheme(s): | 2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and 2016 Executive Incentive Plan ("EIP") | |||||||||||||||||||
Period of return (from / to): | From: 29/Mar/2018 | To: 01/Oct/2018 | ||||||||||||||||||
Balance of unallotted securities under scheme(s) from previous return: | Total of 2,149,159 Ordinary 1p Shares, split: · Under LTIP = 360,485 Ordinary 1p Shares · Under VBP = 1,788,674 Ordinary 1p Shares · Under EIP = nil Ordinary 1p Shares | |||||||||||||||||||
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): | NIL | |||||||||||||||||||
Less: Number of securities issued/allotted under scheme(s) during period: | Total of 166,376 Ordinary 1p Shares, split: · Under LTIP = 39,405 Ordinary 1p Shares · Under VBP = 126,971 Ordinary 1p Shares | |||||||||||||||||||
Less: Number of securities forfeited under scheme(s) during period: | Total of 30,526 Ordinary 1p Shares: · Under LTIP = 30,526 Ordinary 1p Shares · Under VBP = nil Ordinary 1p Shares · Under EIP = nil Ordinary 1p Shares | |||||||||||||||||||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Total of 1,952,257 Ordinary 1p Shares, split: · Under LTIP = 290,554 Ordinary 1p Shares · Under VBP = 1,661,703 Ordinary 1p Shares · Under EIP = nil Ordinary 1p Shares | |||||||||||||||||||
Number and class of securities originally admitted and the date of admission (including any additions): |
| |||||||||||||||||||
-- ends --
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord plc (Nominated Adviser and Broker): | +44 (0) 20 7523 8000 |
Henry Fitzgerald-O'Connor Emma Gabriel
| |
Evercore (Financial Adviser): | +44 (0) 20 7653 6000 |
Julian Oakley Alan Beirne
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.
For further information about Vernalis, please visit www.vernalis.com.